Savara Inc (NASDAQ:SVRA) CFO David L. Lowrance sold 18,480 shares of the stock in a transaction on Thursday, November 1st. The stock was sold at an average price of $9.22, for a total transaction of $170,385.60. The sale was disclosed in a filing with the SEC, which is available through the SEC website.
Shares of SVRA stock opened at $9.39 on Friday. The company has a quick ratio of 10.30, a current ratio of 10.30 and a debt-to-equity ratio of 0.16. Savara Inc has a 12-month low of $8.41 and a 12-month high of $17.19. The firm has a market cap of $329.53 million, a PE ratio of -5.34 and a beta of -0.06.
Savara (NASDAQ:SVRA) last issued its quarterly earnings data on Thursday, August 9th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.36) by ($0.02). On average, research analysts anticipate that Savara Inc will post -1.41 EPS for the current fiscal year.
Institutional investors and hedge funds have recently made changes to their positions in the stock. Metropolitan Life Insurance Co. NY acquired a new position in Savara during the second quarter worth $104,000. MetLife Investment Advisors LLC acquired a new position in Savara during the second quarter worth $148,000. UBS Group AG boosted its holdings in Savara by 1,012.8% during the first quarter. UBS Group AG now owns 14,556 shares of the company’s stock worth $133,000 after purchasing an additional 13,248 shares during the last quarter. Engineers Gate Manager LP acquired a new position in Savara during the third quarter worth $198,000. Finally, Rhumbline Advisers acquired a new position in Savara during the second quarter worth $270,000. Institutional investors and hedge funds own 41.79% of the company’s stock.
Several equities research analysts have recently issued reports on the stock. BidaskClub downgraded shares of Savara from a “buy” rating to a “hold” rating in a research report on Wednesday, August 15th. Zacks Investment Research raised shares of Savara from a “sell” rating to a “hold” rating in a research report on Saturday, September 1st. Roth Capital assumed coverage on shares of Savara in a research report on Monday, August 13th. They set a “neutral” rating and a $12.00 price objective for the company. Canaccord Genuity set a $25.00 price objective on shares of Savara and gave the stock a “buy” rating in a research report on Tuesday, August 14th. Finally, HC Wainwright reissued a “buy” rating and set a $22.00 price objective on shares of Savara in a research report on Friday, August 10th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have issued a buy rating to the company. Savara has an average rating of “Hold” and a consensus target price of $26.80.
Savara Company Profile
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
See Also: How to Use the New Google Finance Tool
Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.